Compare PENN & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PENN | PLSE |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2015 |
| Metric | PENN | PLSE |
|---|---|---|
| Price | $16.15 | $26.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 1 |
| Target Price | $20.83 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 3.9M | 336.6K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,362,900,000.00 | N/A |
| Revenue This Year | $6.85 | $840.00 |
| Revenue Next Year | $3.83 | $287.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.65 | $12.56 |
| 52 Week High | $20.61 | $27.98 |
| Indicator | PENN | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 61.94 |
| Support Level | $15.50 | $17.58 |
| Resistance Level | $18.13 | $26.30 |
| Average True Range (ATR) | 0.62 | 1.81 |
| MACD | -0.14 | 0.57 |
| Stochastic Oscillator | 26.40 | 80.77 |
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.